Skip to main content

Sodium zirconium cyclosilicate Side Effects

Medically reviewed by Philip Thornton, DipPharm. Last updated on Apr 19, 2022.

For the Consumer

Applies to sodium zirconium cyclosilicate: oral powder for suspension

Side effects include:

Edema, hypokalemia.

For Healthcare Professionals

Applies to sodium zirconium cyclosilicate: oral powder for reconstitution

General

The most commonly reported adverse reactions reported during clinical trials included edema and hypokalemia.[Ref]

Cardiovascular

Very common (10% or more): Edema (up to 16.1%)

During clinical trials, edema was reported in 4.4% of patients receiving 5 g/day, 5.9% of patients receiving 10 g/day and 16.1% of patients receiving 15 g/day for up to 28 days (placebo 2.4%). In longer-term trials, 8% to 11% of patients receiving doses less than 15 g/day reported edema, generalized edema and peripheral edema.

Metabolic

Common (1% to 10%): Hypokalemia

Frequency not reported: Increase in sodium bicarbonate concentrations

In clinical trials, 4.1% of patients developed hypokalemia which resolved with dose reduction or discontinuation.

Small, dose-dependent increases in sodium bicarbonate occurred with once daily dosing (1.1 mmol/L at 5 g/day; 2.3 mmol/L at 10 g/day; 2.6 mmol/L at 15 g/day; 0.6 mmol/L in placebo). The clinical significance of this is unknown.

Frequently asked questions

More about sodium zirconium cyclosilicate

Patient resources

Other brands

Lokelma

Professional resources

Related treatment guides

References

1. "Product Information. Lokelma (sodium zirconium cyclosilicate)." Astra-Zeneca Pharmaceuticals (2018):

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.